FindMyKOL
Clinical trialNCT00773474TerminatedPhase 2Interventional

Lonafarnib in Metastatic Breast Cancer

SponsorGeorge SledgeEnrollment29Metastatic Breast Cancer
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

A published phase 2 study reported that lonafarnib was administered as a single agent via continuous or intermittent oral dosing to 76 women with advanced breast cancer who were previously treated with chemotherapy and/or with endocrine therapy. Objective response rates of approximately 10% were observed. This study will determine the rate of progression-free survival of patients with metastatic breast cancer who receive lonafarnib.
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

6 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • Medical & Surgical Specialists, Llc

    Galesburg, Illinois, United States

  • Cancer Care Center of Southern Indiana

    Bloomington, Indiana, United States

  • Indiana University Melvin and Bren Simon Cancer Center

    Indianapolis, Indiana, United States

  • Arnett Cancer Care

    Lafayette, Indiana, United States

  • Horizon Oncology Center

    Lafayette, Indiana, United States

  • Ireland Cancer Center - University Hospitals of Cleveland

    Cleveland, Ohio, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Lonafarnib
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
31 Oct 2008
Primary completion
30 Nov 2010
Completion
30 Nov 2010
Last update posted
18 Feb 2016
Registered enrollment
29
Registry id
NCT00773474
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.